Genocea Biosciences Inc. (NASDAQ:GNCA) had its price objective reduced by stock analysts at Piper Jaffray Cos. from $9.00 to $12.00 in a research report issued on Thursday. The brokerage presently has an “overweight” rating on the stock. Piper Jaffray Cos.’s price objective points to a potential upside of 169.06% from the stock’s current price.
A number of other brokerages have also issued reports on GNCA. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Genocea Biosciences in a research report on Thursday, September 29th. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Finally, Zacks Investment Research lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.96.
Genocea Biosciences (NASDAQ:GNCA) traded down 0.22% during mid-day trading on Thursday, hitting $4.45. 249,853 shares of the stock traded hands. Genocea Biosciences has a 12 month low of $2.56 and a 12 month high of $8.20. The company’s market cap is $126.09 million. The stock’s 50 day moving average is $5.35 and its 200-day moving average is $4.73.
Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. On average, equities research analysts anticipate that Genocea Biosciences will post ($1.63) EPS for the current year.
Several institutional investors have recently made changes to their positions in GNCA. Alpine Partners VI LLC bought a new position in shares of Genocea Biosciences during the second quarter worth $120,000. TFS Capital LLC bought a new position in shares of Genocea Biosciences during the second quarter worth $133,000. FMR LLC raised its position in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock worth $17,401,000 after buying an additional 21,149 shares during the period. Franklin Resources Inc. raised its position in shares of Genocea Biosciences by 4.8% in the second quarter. Franklin Resources Inc. now owns 3,025,300 shares of the company’s stock worth $12,404,000 after buying an additional 138,700 shares during the period. Finally, AXA raised its position in shares of Genocea Biosciences by 1.4% in the second quarter. AXA now owns 595,157 shares of the company’s stock worth $2,440,000 after buying an additional 8,183 shares during the period. Institutional investors own 56.49% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.